Hyderabad, June 29 (NSS): Zydus and Dr Reddy’s announced licensing agreement for co-marketing of Pertuzumab biosimilar, a critical treatment for breast cancer patients in India.
Pertuzumab biosimilar developed by Zydus is a critical treatment for HER2 positive breast cancer and is being launched jointly by Zydus and Dr Reddy’s in India. The product will be marketed by Zydus under the brand name Sigrima™ while Dr Reddy’s will market it under the brand name Womab®.
